Fig. 8

(Abstract O8). Because rodents do not express MIC, we engineered mouse melanoma B16 tumor cells to express sMIC (B16-sMIC). We implanted B16-sMIC into syngeneic host. When tumors grew to 50-100mm3 in size, treatment starts. Four treatments were given: Adoptive transfer of melanoma antigen-specific Pmel CD8 T cells once, B10G5 (CuraB-10) twice 2 week Adoptive transfer of melanoma antigen-specific Pmel CD8 T cells once, control IgG (cIgG) twice 2 week B10G5 alone 4) cIgG alone Tumor growth curve demonstrating that treatment with B10G5 (CuraB-10) effectuates the effect of Pmel CD8 T therapy Survival curve. Tumor volume of 1000mm3 was defined as survival end point. In one experiment, 2/7 animals received B10G5 and Pmel therapy had complete tumor regression. Note: currently Adoptive T cell transfer (ACT) requires prior-depletion of patient’s immune cells with chemotherapy to be effective. With B10G5 therapy, not only lymph depletion is not required prior to ACT, but also ACT is more effective